Core Insights - Auna S.A. has a strong history of beating earnings estimates, with an average surprise of 93.59% over the last two quarters, indicating potential for continued performance in upcoming reports [1][2] Earnings Performance - For the last reported quarter, Auna S.A. achieved earnings of $0.20 per share, exceeding the Zacks Consensus Estimate of $0.15 per share by 33.33% [2] - In the previous quarter, the company reported earnings of $0.33 per share against an expected $0.13 per share, resulting in a surprise of 153.85% [2] Earnings Estimates - Recent estimates for Auna S.A. have been trending upward, with a positive Earnings ESP of +44.00%, suggesting increased analyst optimism regarding the company's near-term earnings potential [5][8] - The combination of a positive Earnings ESP and a Zacks Rank of 3 (Hold) indicates a strong likelihood of another earnings beat [5][8] Predictive Metrics - Stocks with a positive Earnings ESP and a Zacks Rank of 3 or better have historically produced positive surprises nearly 70% of the time, indicating a high probability of exceeding consensus estimates [6] - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, reflecting the latest analyst revisions and potentially more accurate predictions [7]

Core Viewpoint - Middlefield Banc Corp. (MBCN) is positioned well to potentially beat earnings estimates in its upcoming quarterly report, supported by a strong history of exceeding expectations [1]. Earnings Performance - Middlefield Banc has a solid track record of surpassing earnings estimates, with an average surprise of 17.45% over the last two quarters [2]. - In the most recent quarter, the company reported earnings of $0.65 per share against an expectation of $0.64, resulting in a surprise of 1.56% [2]. - For the previous quarter, the consensus estimate was $0.57 per share, while the actual earnings were $0.76 per share, leading to a surprise of 33.33% [2]. Earnings Estimates and Predictions - Estimates for Middlefield Banc have been trending upward, influenced by its history of earnings surprises [5]. - The company currently has a positive Zacks Earnings ESP of +1.54%, indicating that analysts are optimistic about its earnings prospects [8]. - The combination of a positive Earnings ESP and a Zacks Rank of 3 (Hold) suggests a strong possibility of another earnings beat [8]. Statistical Insights - Research indicates that stocks with a positive Earnings ESP and a Zacks Rank of 3 or better have a nearly 70% chance of producing a positive surprise [6]. - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, reflecting the latest analyst revisions [7]. Importance of Earnings ESP - It is crucial for investors to check a company's Earnings ESP prior to its quarterly release to enhance the likelihood of successful investment decisions [10].

Core Insights - The fourth-quarter earnings season is ongoing, with major pharmaceutical companies set to announce their results, including AstraZeneca, Incyte, Gilead Sciences, Vertex Pharmaceuticals, and Moderna [1] Industry Overview - Several large pharmaceutical companies such as Johnson & Johnson, Lilly, AbbVie, Biogen, Merck, and Amgen reported better-than-expected fourth-quarter results, surpassing estimates for both earnings and revenues. In contrast, Novartis and Sanofi had mixed results, with earnings exceeding estimates but revenues falling short [2] - As of February 4, 40% of companies in the Medical sector, representing 73.9% of the sector's market capitalization, reported quarterly earnings. Among these, 87.5% exceeded earnings estimates, and 75% surpassed revenue estimates. Year-over-year, earnings increased by 3.3%, while revenues rose by 9.5%. Overall, fourth-quarter earnings for the Medical sector are expected to decline by 1.5%, while sales are projected to increase by 9.1% compared to the previous year [3] Company-Specific Insights AstraZeneca - AstraZeneca's performance has been mixed, with earnings beating estimates in two of the last four quarters, meeting once, and missing once, resulting in an average surprise of 3.81%. The consensus estimate for fourth-quarter sales is $15.78 billion, with earnings expected at $2.18 per share [5] - Key medicines, particularly cancer drugs and diabetes medicine, are expected to drive fourth-quarter sales, supported by strong demand trends [7] - AstraZeneca is scheduled to report its fourth-quarter and full-year 2025 results on February 10 [8] Incyte - Incyte has a mixed history of earnings surprises, beating estimates in three of the last four quarters, with an average surprise of 14.35%. The consensus estimate for fourth-quarter sales is $1.35 billion, with earnings expected at $1.94 per share [9] - Strong sales of Jakafi and expected growth in Opzelura sales are likely to contribute to revenue growth in the fourth quarter [11][12] - Incyte is also set to report its fourth-quarter and full-year 2025 earnings on February 10 [12] Gilead Sciences - Gilead Sciences has a mixed earnings surprise history, beating estimates in three of the last four quarters, with an average surprise of 7.80%. The consensus estimate for fourth-quarter sales is $7.57 billion, with earnings expected at $1.83 per share [13] - Increased sales from Biktarvy and Descovy, along with growth in the Liver Disease portfolio, are anticipated to drive top-line growth [14] - Gilead is scheduled to report its fourth-quarter and full-year 2025 results on February 10 [15] Vertex Pharmaceuticals - Vertex has a mixed earnings surprise history, beating estimates in two of the last four quarters, with an average surprise of 2.01%. The consensus estimate for fourth-quarter sales is $3.17 billion, with earnings expected at $5.07 per share [16] - Revenue growth is likely to be driven by higher sales of its cystic fibrosis medicine, Trikafta, and contributions from newer drugs [18] - Vertex is set to report its fourth-quarter and full-year 2025 results on February 12 [19] Moderna - Moderna has a strong earnings surprise history, beating estimates in all of the last four quarters, with an average surprise of 31.45%. The consensus estimate for fourth-quarter sales is $661.4 million, with expected earnings showing a loss of $2.60 per share [20] - Revenue is expected to be primarily driven by sales of COVID-19 vaccines, although demand has declined recently [22] - Moderna is scheduled to report its fourth-quarter and full-year 2025 earnings on February 13 [23]

Core Viewpoint - Investors in the Utility - Electric Power sector should consider Avista (AVA) and OGE Energy (OGE) for potential value opportunities, with a closer examination needed to determine which stock offers better value [1] Group 1: Zacks Rank and Earnings Outlook - Avista has a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, while OGE Energy has a Zacks Rank of 3 (Hold) [3] - The Zacks Rank emphasizes stocks with positive revisions to earnings estimates, suggesting that AVA has an improving earnings outlook [3] Group 2: Valuation Metrics - AVA has a forward P/E ratio of 15.04, compared to OGE's forward P/E of 18.09, indicating that AVA may be undervalued relative to OGE [5] - The PEG ratio for AVA is 2.13, while OGE's PEG ratio is 2.59, suggesting AVA has a more favorable growth outlook relative to its valuation [5] - AVA's P/B ratio is 1.27, while OGE's P/B ratio is 1.85, further indicating that AVA is potentially undervalued [6] Group 3: Value Grades - AVA has earned a Value grade of B, while OGE has a Value grade of C, suggesting that AVA is the more attractive option for value investors [6]

Core Viewpoint - Investors are evaluating Jacobs Solutions (J) and Advanced Drainage Systems (WMS) to determine which stock offers better value for investment at the current time [1] Group 1: Zacks Rank and Earnings Outlook - Both Jacobs Solutions and Advanced Drainage Systems currently hold a Zacks Rank of 2 (Buy), indicating a positive earnings outlook due to favorable analyst estimate revisions [3] - The Zacks Rank is a reliable indicator for value investors as it emphasizes companies with improving earnings forecasts [2] Group 2: Valuation Metrics - Jacobs Solutions has a forward P/E ratio of 20.88, while Advanced Drainage Systems has a higher forward P/E of 29.09 [5] - The PEG ratio for Jacobs Solutions is 1.54, compared to Advanced Drainage Systems' PEG ratio of 2.26, indicating Jacobs Solutions may be undervalued relative to its expected earnings growth [5] - Jacobs Solutions has a P/B ratio of 5.07, while Advanced Drainage Systems has a P/B ratio of 7, further suggesting that Jacobs Solutions is a more attractive value option [6] Group 3: Value Grades - Based on the valuation metrics, Jacobs Solutions has earned a Value grade of B, whereas Advanced Drainage Systems has received a Value grade of D, indicating a stronger value proposition for Jacobs Solutions [6]

Core Viewpoint - Concentrix Corporation (CNXC) is currently viewed as a better investment opportunity compared to Bowman Consulting (BWMN) based on various valuation metrics and earnings outlook [1][3][7] Valuation Metrics - CNXC has a forward P/E ratio of 3.40, significantly lower than BWMN's forward P/E of 22.17, indicating that CNXC may be undervalued [5] - The PEG ratio for CNXC is 0.39, while BWMN's PEG ratio stands at 1.15, suggesting that CNXC offers better value relative to its expected earnings growth [5] - CNXC's P/B ratio is 0.91, compared to BWMN's P/B of 2.33, further supporting the notion that CNXC is undervalued [6] Earnings Outlook - CNXC has a Zacks Rank of 2 (Buy), indicating a positive earnings estimate revision trend, while BWMN has a Zacks Rank of 4 (Sell), reflecting a less favorable outlook [3][7] - The improving earnings outlook for CNXC enhances its attractiveness as a value investment [7] Value Grades - CNXC holds a Value grade of A, while BWMN has a Value grade of C, reinforcing the assessment that CNXC is the superior value option at this time [6]

Core Viewpoint - The article compares Fox Corporation (FOX) and Fox (FOXA) to determine which stock is more attractive to value investors [1] Group 1: Zacks Rank and Earnings Outlook - Fox Corporation has a Zacks Rank of 2 (Buy), indicating a positive earnings estimate revision trend, while Fox has a Zacks Rank of 3 (Hold) [3] - The improving earnings outlook for FOX suggests it is a more favorable option for investors [7] Group 2: Valuation Metrics - FOX has a forward P/E ratio of 12.51, compared to FOXA's forward P/E of 14.18 [5] - FOX's PEG ratio is 7.92, while FOXA's PEG ratio is 8.52, indicating FOX may be undervalued relative to its expected EPS growth [5] - FOX has a P/B ratio of 2.35, whereas FOXA has a P/B of 2.61, further supporting FOX's valuation attractiveness [6] - These metrics contribute to FOX's Value grade of B and FOXA's Value grade of C [6]

Core Insights - Rollins, Inc. (ROL) is scheduled to report its fourth-quarter 2025 results on February 11, with a strong earnings surprise history, surpassing the Zacks Consensus Estimate in two of the last four quarters and matching twice, averaging a 3.2% earnings surprise [1] Revenue Expectations - The Zacks Consensus Estimate for revenues in the upcoming quarter is $922.1 million, reflecting a year-over-year increase of 10.8% [2] - Residential revenues are estimated at $407 million, indicating a 10.3% increase from the previous year, while commercial revenues are expected to rise 11.4% year over year to $312.4 million [3] - Termite and ancillary revenues are projected at $195.5 million, suggesting a 13.4% growth year over year, with franchise revenues estimated at $4.3 million, showing a marginal rise [3] - U.S. revenues are pegged at $858.3 million, indicating an 11.3% increase from the year-ago quarter, while revenues from other countries are anticipated to grow 9.6% year over year to $66.9 million [5] Growth Drivers - The anticipated revenue growth is attributed to Orkin's expansion, which has the highest customer retention rate among the company's service lines, and the utilization of advanced digital tools such as BOSS, VRM, Orkin 2.0, BizSuite, and InSite [4] - Recent acquisitions of Saela Holdings and FPC Holdings are expected to enhance geographical exposure to favorable regions, while increased media engagement through social media platforms like TikTok and Facebook is likely to boost brand popularity [6] Earnings Outlook - The consensus estimate for earnings is set at 27 cents per share, indicating a year-over-year growth of 17.4% [6] - The bottom line is expected to benefit from the company's CPI-plus focused pricing strategies, which aim to keep prices above the general Consumer Price Index (CPI) rate to mitigate inflation effects [7] Earnings Prediction Model - The current model does not predict a definitive earnings beat for ROL, as it has an Earnings ESP of 0.00% and a Zacks Rank of 3 (Hold) [8]

Core Insights - DraftKings Inc. (DKNG) is set to report its fourth-quarter 2025 results on February 12, with an earnings miss of 8.3% in the last quarter [2] Financial Estimates - The Zacks Consensus Estimate for fourth-quarter adjusted earnings per share has risen to 50 cents from 45 cents over the past 30 days, compared to an adjusted loss per share of 28 cents in the same quarter last year [3] - Revenue consensus is projected at $1.99 billion, reflecting a 42.9% year-over-year increase [3] Revenue Drivers - Strong sportsbook engagement, particularly around the NFL and early NBA seasons, is expected to have significantly contributed to fourth-quarter revenues, with increased customer activity and improved retention [4] - Continued acceleration in iGaming growth, driven by more active users and higher spending per customer, is likely to have provided a more stable revenue stream [5] - Marketing leverage and brand partnerships, especially with ESPN and NBCUniversal, have enhanced customer engagement and brand reach without substantial additional spending [6] Earnings Performance - Structural margin improvements, driven by a richer bet mix and disciplined promotional spending, are anticipated to have positively impacted earnings [7] - Operating leverage from previous investments in technology and customer management is expected to have limited cost growth despite increased volumes [7] Earnings Prediction Model - The current model does not predict an earnings beat for DraftKings, as it lacks a positive Earnings ESP and holds a Zacks Rank of 4 (Sell) [8][10]

Core Viewpoint - Smurfit Westrock PLC (SW) is expected to report fourth-quarter 2025 results on February 11, with revenues projected at $7.67 billion, reflecting a 1.7% year-over-year growth, and earnings per share (EPS) estimated at 46 cents, up from 34 cents in the previous year [1][5]. Financial Estimates - The Zacks Consensus Estimate for revenues is $7.67 billion, indicating a 1.7% increase from the same quarter last year [1][5]. - The EPS consensus is set at 46 cents, showing a rise from 34 cents year-over-year [1][5]. - The earnings surprise history shows that the company has beaten the Zacks Consensus Estimate once in the last four quarters, with an average negative surprise of 18.4% [2]. Segment Performance - The Europe, MEA, and APAC segment is projected to generate revenues of $2.74 billion, up from $2.51 billion in the fourth quarter of 2024, with adjusted EBITDA estimated at $426 million, an increase from $371 million [7]. - North America's revenue estimate for Q4 2025 is $4.49 billion, slightly down from $4.52 billion reported in the previous year, with adjusted EBITDA expected to be $716 million, indicating a 0.8% year-over-year growth [8]. - The LATAM segment's revenue is estimated at $533 million, up from $505 million, but adjusted EBITDA is projected to decline to $116 million from $121 million in the prior-year quarter [9]. Market Trends and Challenges - Demand for corrugated packaging and containerboard remains stable, driven by e-commerce growth and the need for sustainable packaging solutions [3]. - However, weak volumes in Europe and lower box demand are anticipated to negatively impact quarterly results [4][5]. - Merger-related costs are expected to affect performance and free cash flow margin, although pricing actions and cost-saving initiatives may mitigate some of these challenges [6]. Stock Performance - Smurfit Westrock's stock has declined by 14.2% over the past year, compared to a 6.1% decline in the industry [11].